insights_auto
Nega DEVA tushdi 2,47%?
Batafsil oʻrganishchevron_right
DEVA:IST
Deva Holding AS
80,95 TRY
arrow_downward
-2,47%(-2,05) 1K
13-okt, 18:10:00 (GMT+3) · TRY
search
Barcha belgilar
| Belgi | Narxi | Oʻzgartirishlar | Dinamika (%) |
|---|
insights_autoDEVA tikeri uchun statistika yaratilmoqda...
Ochish
82,65 TRY
Yuqori
83,25 TRY
Past
80,15 TRY
Bozor kapitali
16,19 mlrd
Oʻrtacha hajm
653,35 ming
Hajmi
306,70 ming
52 haftalik eng yuqori
109,30 TRY
52 haftalik eng past
57,50 TRY
Aksiya boʻyicha daromad
-4,21 TRY
Muomaladagi aksiyalar
200,02 mln
Xodimlar soni
3 ming
Ochish
82,65 TRY
Yuqori
83,25 TRY
Past
80,15 TRY
Bozor kapitali
16,19 mlrd
Oʻrtacha hajm
653,35 ming
Hajmi
306,70 ming
52 haftalik eng yuqori
109,30 TRY
52 haftalik eng past
57,50 TRY
Aksiya boʻyicha daromad
-4,21 TRY
Muomaladagi aksiyalar
200,02 mln
Xodimlar soni
3 ming
Yangiliklar
Internet manbalari va yangilik hamkorlarimizdan
Seeking Alpha
·
36 daqiqa oldin
Biomea Fusion, Inc. (BMEA) Discusses BMF-650 Phase I Topline Results and Potential for Separating GI Side Effects from Weight Loss - Slideshow (NASDAQ:BMEA) 2026-10-14
Yahoo Finance
·
2 soat oldin
Dow, S&P 500, Nasdaq Futures Mixed Amid Rising Oil Prices Ahead Of CPI Data: BAC, RIVN, SLS, GME Stocks In Focus
The Dark Side Of The Boom
·
6 daqiqa oldin
Last Man Standing: The One Trick Pony Is Now Holding Up the S&P
Bloomberg.com
·
7 soat oldin
Asia Stocks to Gain on Signal for Fewer Fed Hikes: Markets Wrap
Profil
DEVA Holding A.Ş. is a Turkish pharmaceutical company operating since 1958. Its principal activities include the development, manufacture and marketing of human pharmaceuticals and active pharmaceutical ingredients. The company also operates in veterinary medicines, cologne, medical ampoules and food supplements.
A majority stake in the company was acquired by EastPharma in 2006. DEVA Holding is listed on Borsa Istanbul, and its chairman and chief executive officer is Philipp Haas.
As of 2025, the company had more than 675 products across 15 therapeutic areas. According to IQVIA data cited in its annual report, DEVA ranked third in the Turkish pharmaceutical market by unit sales in 2025, with a market share of 4.5%. Wikipedia
Deva Holding AS haqida